CA2458047A1 - Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires - Google Patents

Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires Download PDF

Info

Publication number
CA2458047A1
CA2458047A1 CA002458047A CA2458047A CA2458047A1 CA 2458047 A1 CA2458047 A1 CA 2458047A1 CA 002458047 A CA002458047 A CA 002458047A CA 2458047 A CA2458047 A CA 2458047A CA 2458047 A1 CA2458047 A1 CA 2458047A1
Authority
CA
Canada
Prior art keywords
seq
peptide
phage
peptides
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002458047A
Other languages
English (en)
Inventor
Renata Pasqualini
Wadih Arap
Mikhail G. Kolonin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/027692 external-priority patent/WO2002020769A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2458047A1 publication Critical patent/CA2458047A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/28—Gramicidins A, B, D; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions et des procédés d'identification et d'utilisation de peptides de ciblage des tissus adipeux et placentaires. Selon certaines formes d'exécution, les peptides de ciblage comprennent une partie ou la totalité des numéros de séquences: SEQ ID NO:5-11, SEQ ID NO:13-22 ou SEQ ID NO:144. Les peptides peuvent être liés à divers agents thérapeutiques pour une administration ciblée. Les peptides de ciblage des tissus adipeux peuvent être utilisés dans des procédés de contrôle du poids, visant à induire une perte de poids et à traiter le syndrome de la lipodystrophie. Le ciblage des tissu adipeux peut également être effectué au moyen d'autres fractions de liaison ciblées sélectivement sur des récepteurs adipeux tels qu'un complexe de protéines du récepteur de la prohibitine. Les peptides de ciblage des tissus placentaires peuvent être utilisés pour créer une interférence avec la grossesse, induire le travail et/ou pour l'administration ciblée d'agents thérapeutiques sur le placenta et/ou le foetus. Selon d'autres formes d'exécution, des récepteurs, identifiés par liaison aux peptides ciblant les tissus placentaires, peuvent être utilisés pour cribler des composés à pouvoir tératogène potentiel. Un exemple de récepteur placentaire est FcRn/.beta.¿2?M, et les composés qui se lient à FcRn/.beta.¿2?M sont des agents tératogènes potentiels.
CA002458047A 2001-09-07 2002-08-30 Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires Abandoned CA2458047A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2001/027692 WO2002020769A1 (fr) 2000-09-08 2001-09-07 Peptides de ciblage humains et murins identifies par expression phagique
USPCT/US01/27692 2001-09-07
PCT/US2002/027836 WO2003022991A2 (fr) 2001-09-07 2002-08-30 Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires

Publications (1)

Publication Number Publication Date
CA2458047A1 true CA2458047A1 (fr) 2003-03-20

Family

ID=21742817

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002458047A Abandoned CA2458047A1 (fr) 2001-09-07 2002-08-30 Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires

Country Status (4)

Country Link
EP (1) EP1497314A4 (fr)
AU (1) AU2002323543A1 (fr)
CA (1) CA2458047A1 (fr)
WO (1) WO2003022991A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7598341B2 (en) * 2003-10-31 2009-10-06 Burnham Institue For Medical Research Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
WO2005065418A2 (fr) * 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions et procedes d'utilisation de peptides de ciblage pour le diagnostic et la therapie
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2007020405A2 (fr) * 2005-08-12 2007-02-22 Cartela R & D Ab Nouveaux peptides et utilisations associees
CN103458911B (zh) 2011-02-11 2016-02-24 密歇根大学董事会 肽组合物和用于治疗患者的方法
CA3003760A1 (fr) * 2014-11-03 2016-05-12 Tsinghua University Medicament destine a inhiber la differenciation des cellules adipeuses et la resistance a l'insuline
CN114469891B (zh) * 2021-12-29 2023-01-24 中山大学附属第一医院 一种酶敏感外壳的小分子药物/治疗基因联合递送系统及其制备方法和应用
CN114272390B (zh) * 2021-12-29 2022-09-02 中山大学附属第一医院 一种微环境靶向联合细胞靶向肿瘤抑制载体及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
DE19605175A1 (de) * 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
CA2283474A1 (fr) * 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolement de ligands peptidiques a specificite tissulaire et utilisation de ces derniers pour cibler des substances pharmaceutiques sur des organes
FR2797689B1 (fr) * 1999-08-16 2003-06-27 Pasteur Sanofi Diagnostics Utilisation de composes synthetiques pour des immunodosages
GB9929471D0 (en) * 1999-12-13 2000-02-09 Proteom Ltd Complementary peptide ligande generated from higher eukaryote genome sequences
CN1419565A (zh) * 2000-01-21 2003-05-21 伯纳姆研究所 具有促细胞程序死亡活性的嵌合前列腺归巢肽
AU2001288843A1 (en) * 2000-09-08 2002-03-22 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display

Also Published As

Publication number Publication date
AU2002323543A1 (en) 2003-03-24
WO2003022991A3 (fr) 2004-10-28
WO2003022991A2 (fr) 2003-03-20
EP1497314A2 (fr) 2005-01-19
EP1497314A4 (fr) 2007-10-10

Similar Documents

Publication Publication Date Title
US8846859B2 (en) Compositions and methods of use of targeting peptides against placenta and adipose tissues
EP1322755B1 (fr) Peptides de ciblage humains et murins identifies par expression phagique
US8710017B2 (en) Human and mouse targeting peptides identified by phage display
AU2007216854B2 (en) Human and mouse targeting peptides identified by phage display
US20120003152A1 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
CA2458047A1 (fr) Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires
US20040048243A1 (en) Methods and compositions for in vitro targeting
CA2730627C (fr) Peptides de ciblage humains et murins identifies par expression phagique
Class et al. Patent application title: COMPOSITIONS AND METHODS OF USE OF TARGETING PEPTIDES AGAINST PLACENTA AND ADIPOSE TISSUES Inventors: Renata Pasqualini (Houston, TX, US) Renata Pasqualini (Houston, TX, US) Wadih Arap (Houston, TX, US) Mikhail G. Kolonin (Houston, TX, US) Mikhail G. Kolonin (Houston, TX, US)
Class et al. Patent application title: HUMAN AND MOUSE TARGETING PEPTIDES IDENTIFIED BY PHAGE DISPLAY Inventors: Wadih Arap (Houston, TX, US) Renata Pasqualini (Houston, TX, US) Renata Pasqualini (Houston, TX, US) Assignees: Board of Regents, The University of Texas System
ES2353882T3 (es) Péptidos dirigidos a humanos y ratones identificados por fago.
AU2007203251A1 (en) Compositions and methods for targeting peptides in humans in vivo

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead